One-size-fits-all pancreatic cancer vaccine showed promise in early trial
13 days ago
- #KRAS-mutation
- #pancreatic-cancer
- #cancer-vaccine
- A one-size-fits-all vaccine shows promise in preventing pancreatic cancer recurrence.
- Pancreatic cancer has a low five-year survival rate (13%) and high recurrence rate (80%).
- The vaccine targets KRAS gene mutations, common in many cancers including pancreatic and colorectal.
- Unlike personalized vaccines, this one is off-the-shelf and doesn't require tumor sequencing.
- Phase 1 trial involved 25 patients (20 pancreatic, 5 colorectal) with KRAS mutations.
- 85% of participants mounted an immune response, with some showing robust responses.
- The vaccine triggered immune responses beyond KRAS mutations in nearly 70% of participants.
- Average survival post-vaccination was 29 months, with 15+ months recurrence-free.
- The vaccine uses lipophilic peptides with a tail that activates immune cells in lymph nodes.
- Phase 2 trials are underway to test durability and compare effectiveness to standard care.